New Interim, Real-World Data Provides Additional Insights on Hyperkalemia and Safety of Kerendia® (finerenone) for Patients with Chronic Kidney Disease Associated with Type 2 Diabetes streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
New Interim, Real-World Data Provides Additional Insights on Hyperkalemia and Safety of Kerendia® (finerenone) for Patients with Chronic Kidney Disease Associated with Type 2 Diabetes valdostadailytimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from valdostadailytimes.com Daily Mail and Mail on Sunday newspapers.
FIGARO-BM, an exploratory human biomarker study, provides additional insight on finerenone's mechanism of action in blocking mineralocorticoid receptor (MR) overactivation1New data presented at the American Society of Nephrology’s (ASN) Kidney Week 2023WHIPPANY, N.J. (BUSINESS WIRE) At the American Society of Neph.
Dapagliflozin became the first SGLT2 inhibitor approved for CKD alone just over 2 years ago, but uptake has lagged. Could a similar label gain for empagliflozin, plus a new recommendation, spark change?